Prostate Cancer News and Research

Latest Prostate Cancer News and Research

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Bavarian Nordic A/S announced today that it has received notification that the U.S. Food and Drug Administration (FDA) has accepted all the actions taken by the company to address the observations made during the inspection of the manufacturing facilities in 2009. This was the last step along with the clinical and preclinical data that will be used to potentially support the use of IMVAMUNE® following a declared emergency.

18 Mar 2010

Early baldness may not be associated with risk of prostate cancer

Men who start losing their hair at an early age may be less likely to develop prostate cancer in the future, new research suggests.

18 Mar 2010

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, today announced the availability of Companion Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology Software. BioImagene’s Companion Algorithms are unique in the digital pathology industry as they are specific to a biomarker and a tissue type. Therefore, pathologists are not faced with the challenges of customizing generic algorithms in order to make them work.

18 Mar 2010

Harbor BioSciences receives approval for stock listing transfer to The Nasdaq Capital Market

Harbor BioSciences, Inc. today announced that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market from The Nasdaq Global Market, effective at the opening of business on March 18, 2010. The company's common stock will continue to be traded under the symbol "HRBR." The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as the Nasdaq Global Market.

18 Mar 2010

Watchful waiting is viable option for many men with low risk prostate cancer

Active surveillance, also referred to as watchful waiting, is a viable option for many men with low risk prostate cancer although the concept continues to cause distress and confusion. James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed the role of active surveillance as well as other treatment options recommended in the recently updated NCCN Guidelines™ for Prostate Cancer at the NCCN 15th Annual Conference.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Health Discovery Corporation and Smart Personalized Medicine, LLC announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services.

From Quest Diagnostics 17 Mar 2010

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

One of the most dangerous characteristics of cancer is its ability to metastasize, or spread through the body. For this reason, oncologists have a major need for better tests to detect cells that break away from primary tumors to travel to other parts of the body.

17 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

Cancer news coverage should also focus on hospice and end-of-life care

Newspaper and magazine reports about cancer appear more likely to discuss aggressive treatment and survival than death, treatment failure or adverse events, and almost none mention end-of-life palliative or hospice care, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

17 Mar 2010

Boosting radiation dose for prostate cancer patients does not increase severity of side effects

Boosting the radiation dose given to prostate cancer patients to a level that cut tumor recurrence in half did not increase the severity of side effects reported by patients up to a decade later. The study led by Massachusetts General Hospital Cancer Center researchers also found that patients characterized the impact of continuing side effects on their quality of life as considerably less bothersome than would be expected, based on earlier studies.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

Levels of perceived cancer risk can affect health and longevity

Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.

16 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

GTx reacquires full rights to Ostarine

GTx, Inc. today provided a company update and reported financial results for the fourth quarter and full year 2009.

15 Mar 2010

Multimedia software program developed to help prostate cancer patients make treatment decisions

Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their families make treatment decisions.

15 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Early baldness may not be associated with risk of prostate cancer

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

Harbor BioSciences receives approval for stock listing transfer to The Nasdaq Capital Market

Watchful waiting is viable option for many men with low risk prostate cancer

Novel findings point to new therapeutic approaches for common types of cancer

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Cancer news coverage should also focus on hospice and end-of-life care

Boosting radiation dose for prostate cancer patients does not increase severity of side effects

Key cellular defect in protein synthesis can lead to cancer susceptibility

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Levels of perceived cancer risk can affect health and longevity

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

GTx reacquires full rights to Ostarine

Multimedia software program developed to help prostate cancer patients make treatment decisions

New method to better study prostate cancer

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in